A trial to compare changes in disability progression in multiple sclerosis patients on Natalizumab (NTZ) standard interval dose (q4 weeks, SID) and on extended interval dose (q6-8 weeks, EID) utilizing Patient-derived Multiple Sclerosis Severity Score (P-MSSS)

Trial Profile

A trial to compare changes in disability progression in multiple sclerosis patients on Natalizumab (NTZ) standard interval dose (q4 weeks, SID) and on extended interval dose (q6-8 weeks, EID) utilizing Patient-derived Multiple Sclerosis Severity Score (P-MSSS)

Completed
Phase of Trial: Phase II

Latest Information Update: 06 May 2016

At a glance

  • Drugs Natalizumab (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 May 2016 New trial record
    • 21 Apr 2016 Results presented at the 68th Annual Meeting of the American Academy of Neurology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top